Skip to main content

Table 2 Side effects of PARP inhibitors

From: Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review

   Olaparib SOLO2/ENGOT-Ov21 (n = 195) [51] Niraparib NOVA/ENGOT-OV16 (n = 367) [52] Rucaparib ARIEL2 (n = 204)/ARIEL3 (n = 374) [53, 54] Veliparib (n = 50) [55]
Grade 3 and 4 Adverse Events Hematological Anemia 38 (18%)
Neutropenia 8 (4%)
Thrombocytopenia 2 (1%)
Anemia 93 (25.3%)
Neutropenia 72 (19.6%)
Thrombocytopenia 124
(33.8%)
Anemia 45 (22%)/70 (19%)
Neutropenia 16 (7%)/25 (7%)
Thrombocytopenia 5 (2%)/19 (5%)
Leukopenia 1 (2%) Neutropenia 1 (2%)
Thrombocytopenia 1 (2%)
Non-hematological Fatigue 8 (4%) Abdominal pain 5 (3%)
Nausea 5 (3%) Vomiting 5 (3%)
Hypertension 30 (8.2%)
Fatigue 30 (8.2%) Abdominal pain 4 (1.1%)
Nausea 11 (3.0%)
Elevated AST/ALT 25 (13%)/39 (10%) Fatigue 18 (9%)/25 (7%)
Abdominal pain 5 (2%)/9 (2%)
Nausea 9 (4%)/14 (4%)
Nausea 2 (4%)
Metabolism/nutrition 1 (2%)
Other investigations 6 (12%)
Serious Adverse Events Total 35 (18%) Total 110 (30%) [16] ARIEL2: total 50 (25%)
ARIEL3: total 78 (21%)
Total 12 (24%)
Individual Anemia 7 (4%)
Abdominal pain 3 (2%) Intestinal obstruction 3 (2%)
  ARIEL2:
Intestinal obstruction 10 (5%)
Anemia 9 (4%)
ARIEL3:
Anemia 16 (4%)
Pyrexia 6 (2%)
Vomiting 6 (2%)
Intestinal obstruction 3 (1%)
 
Dose Changes due to Adverse Events   Dose reductions 49 (25%)
Discontinuations 21 (11%)
Dose reductions: 244 (66.5%)
Discontinuations: 54 (14.7%)
ARIEL2:
Dose reductions: 80 (39%) Discontinuations: 19 (9%)
ARIEL3:
Dose reductions: 203 (55%)
Discontinuations: 50 (13%)
Dose Reductions: 31 (62%)
Discontinuations: 31 (62%)a